

Opioid Induced Constipation Drugs-India Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O30C4E05BA7MEN.html>

Date: May 2018

Pages: 137

Price: US\$ 2,980.00 (Single User License)

ID: O30C4E05BA7MEN

Abstracts

Report Summary

Opioid Induced Constipation Drugs-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Induced Constipation Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Opioid Induced Constipation Drugs 2013-2017, and development forecast 2018-2023

Main market players of Opioid Induced Constipation Drugs in India, with company and product introduction, position in the Opioid Induced Constipation Drugs market
Market status and development trend of Opioid Induced Constipation Drugs by types and applications

Cost and profit status of Opioid Induced Constipation Drugs, and marketing status

Market growth drivers and challenges

The report segments the India Opioid Induced Constipation Drugs market as:

India Opioid Induced Constipation Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North India

Northeast India

East India

South India

West India

India Opioid Induced Constipation Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Lubiprostone

Methyl Naltrexone Bromide

Naldemedine

Alvimopan

Other

India Opioid Induced Constipation Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

India Opioid Induced Constipation Drugs Market: Players Segment Analysis (Company
and Product introduction, Opioid Induced Constipation Drugs Sales Volume, Revenue,
Price and Gross Margin):

Ironwood Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Pfizer

Progenics Pharmaceuticals Inc

Shionogi & Co., Ltd

Allergan Plc

Nektar Therapeutics

Purdue Pharma

S.L.A. Pharma AG

Mundipharma International Limited

Ono Pharmaceutical Co., Ltd

Takeda Pharmaceutical Company Limited

Theravance Biopharma Inc

Valeant Pharmaceuticals International

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OPIOID INDUCED CONSTIPATION DRUGS

- 1.1 Definition of Opioid Induced Constipation Drugs in This Report
- 1.2 Commercial Types of Opioid Induced Constipation Drugs
 - 1.2.1 Lubiprostone
 - 1.2.2 Methyl Naltrexone Bromide
 - 1.2.3 Naldemedine
 - 1.2.4 Alvimopan
 - 1.2.5 Other
- 1.3 Downstream Application of Opioid Induced Constipation Drugs
 - 1.3.1 Hospital Pharmacies
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacies
- 1.4 Development History of Opioid Induced Constipation Drugs
- 1.5 Market Status and Trend of Opioid Induced Constipation Drugs 2013-2023
 - 1.5.1 United States Opioid Induced Constipation Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Opioid Induced Constipation Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Opioid Induced Constipation Drugs in United States 2013-2017
- 2.2 Consumption Market of Opioid Induced Constipation Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Opioid Induced Constipation Drugs in United States by Regions
 - 2.2.2 Revenue of Opioid Induced Constipation Drugs in United States by Regions
- 2.3 Market Analysis of Opioid Induced Constipation Drugs in United States by Regions
 - 2.3.1 Market Analysis of Opioid Induced Constipation Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Opioid Induced Constipation Drugs in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Opioid Induced Constipation Drugs in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Opioid Induced Constipation Drugs in The West 2013-2017
 - 2.3.5 Market Analysis of Opioid Induced Constipation Drugs in The South 2013-2017

- 2.3.6 Market Analysis of Opioid Induced Constipation Drugs in Southwest 2013-2017
- 2.4 Market Development Forecast of Opioid Induced Constipation Drugs in United States 2018-2023
 - 2.4.1 Market Development Forecast of Opioid Induced Constipation Drugs in United States 2018-2023
 - 2.4.2 Market Development Forecast of Opioid Induced Constipation Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole United States Market Status by Types
 - 3.1.1 Consumption Volume of Opioid Induced Constipation Drugs in United States by Types
 - 3.1.2 Revenue of Opioid Induced Constipation Drugs in United States by Types
- 3.2 United States Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in New England
 - 3.2.2 Market Status by Types in The Middle Atlantic
 - 3.2.3 Market Status by Types in The Midwest
 - 3.2.4 Market Status by Types in The West
 - 3.2.5 Market Status by Types in The South
 - 3.2.6 Market Status by Types in Southwest
- 3.3 Market Forecast of Opioid Induced Constipation Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Opioid Induced Constipation Drugs in United States by Downstream Industry
- 4.2 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry in New England
 - 4.2.2 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry in The Middle Atlantic
 - 4.2.3 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry in The Midwest
 - 4.2.4 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry in The West
 - 4.2.5 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry

in The South

4.2.6 Demand Volume of Opioid Induced Constipation Drugs by Downstream Industry
in Southwest

4.3 Market Forecast of Opioid Induced Constipation Drugs in United States by
Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Opioid Induced Constipation Drugs Downstream Industry Situation and Trend
Overview

CHAPTER 6 OPIOID INDUCED CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Opioid Induced Constipation Drugs in United States by Major
Players

6.2 Revenue of Opioid Induced Constipation Drugs in United States by Major Players

6.3 Basic Information of Opioid Induced Constipation Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Opioid Induced Constipation
Drugs Major Players

6.3.2 Employees and Revenue Level of Opioid Induced Constipation Drugs Major
Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 OPIOID INDUCED CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Ironwood Pharmaceuticals Inc

7.1.1 Company profile

7.1.2 Representative Opioid Induced Constipation Drugs Product

7.1.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of
Ironwood Pharmaceuticals Inc

7.2 Daiichi Sankyo Co Ltd

7.2.1 Company profile

- 7.2.2 Representative Opioid Induced Constipation Drugs Product
- 7.2.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd
- 7.3 Pfizer
 - 7.3.1 Company profile
 - 7.3.2 Representative Opioid Induced Constipation Drugs Product
 - 7.3.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.4 Progenics Pharmaceuticals Inc
 - 7.4.1 Company profile
 - 7.4.2 Representative Opioid Induced Constipation Drugs Product
 - 7.4.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Progenics Pharmaceuticals Inc
- 7.5 Shionogi & Co., Ltd
 - 7.5.1 Company profile
 - 7.5.2 Representative Opioid Induced Constipation Drugs Product
 - 7.5.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Shionogi & Co., Ltd
- 7.6 Allergan Plc
 - 7.6.1 Company profile
 - 7.6.2 Representative Opioid Induced Constipation Drugs Product
 - 7.6.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc
- 7.7 Nektar Therapeutics
 - 7.7.1 Company profile
 - 7.7.2 Representative Opioid Induced Constipation Drugs Product
 - 7.7.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Nektar Therapeutics
- 7.8 Purdue Pharma
 - 7.8.1 Company profile
 - 7.8.2 Representative Opioid Induced Constipation Drugs Product
 - 7.8.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Purdue Pharma
- 7.9 S.L.A. Pharma AG
 - 7.9.1 Company profile
 - 7.9.2 Representative Opioid Induced Constipation Drugs Product
 - 7.9.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of S.L.A. Pharma AG
- 7.10 Mundipharma International Limited

- 7.10.1 Company profile
- 7.10.2 Representative Opioid Induced Constipation Drugs Product
- 7.10.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Mundipharma International Limited
- 7.11 Ono Pharmaceutical Co., Ltd
 - 7.11.1 Company profile
 - 7.11.2 Representative Opioid Induced Constipation Drugs Product
 - 7.11.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Ono Pharmaceutical Co., Ltd
- 7.12 Takeda Pharmaceutical Company Limited
 - 7.12.1 Company profile
 - 7.12.2 Representative Opioid Induced Constipation Drugs Product
 - 7.12.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
- 7.13 Theravance Biopharma Inc
 - 7.13.1 Company profile
 - 7.13.2 Representative Opioid Induced Constipation Drugs Product
 - 7.13.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Theravance Biopharma Inc
- 7.14 Valeant Pharmaceuticals International
 - 7.14.1 Company profile
 - 7.14.2 Representative Opioid Induced Constipation Drugs Product
 - 7.14.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
- 7.15 Cosmo Pharmaceuticals SA
 - 7.15.1 Company profile
 - 7.15.2 Representative Opioid Induced Constipation Drugs Product
 - 7.15.3 Opioid Induced Constipation Drugs Sales, Revenue, Price and Gross Margin of Cosmo Pharmaceuticals SA
- 7.16 Daewoong Pharmaceutical
- 7.17 C.B. Fleet Company
- 7.18 Sucampo Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS

- 8.1 Industry Chain of Opioid Induced Constipation Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS

- 9.1 Cost Structure Analysis of Opioid Induced Constipation Drugs
- 9.2 Raw Materials Cost Analysis of Opioid Induced Constipation Drugs
- 9.3 Labor Cost Analysis of Opioid Induced Constipation Drugs
- 9.4 Manufacturing Expenses Analysis of Opioid Induced Constipation Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF OPIOID INDUCED CONSTIPATION DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Opioid Induced Constipation Drugs-India Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O30C4E05BA7MEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O30C4E05BA7MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970